Adrenocortical carcinoma (ACC) is a rare tumor and prognosis is overall poor but heterogeneous. Mitotane (MT) has been used for treatment of ACC for decades, either alone or in combination with cytotoxic chemotherapy. Even at doses up to 6 g per day, more than half of the patients do not achieve targeted plasma concentration (14-20 mg/L) even after many months of treatment which is caused by low water solubility and unfavorable pharmacokinetic properties such as poor bioavailability and high volume of distribution of MT.
Introduction
Adrenocortical carcinoma (ACC) is a highly aggressive malignant disease with a high risk of recurrence even after complete resection and heterogeneous but generally poor prognosis in advanced stages [1] [2] [3] . In the majority of the cases, patients with ACC present with hormonal excess, mostly Cushing's syndrome and symptoms of sex steroid excess. Patients without hormone overproduction generally are diagnosed due to symptoms of local tumor growth or symptomatic metastases. The therapeutic challenge is to both control hormone excess and to combat tumor progression [4] .
The only approved treatment for ACC is the adrenolytic drug 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane, better known by its trivial name mitotane (MT). MT is used both as adjuvant therapy after complete tumor resection and as palliative treatment in case of advance disease. Only recently, the presumed key molecular mechanism of action was shown to be inhibition of sterol-O-acyl transferase 1 [5] but additional drug effects, e.g. at the level of mitochondria have been reported [6, 7] . Based on the results obtained from a large randomized phase III clinical trial, the combination of oral MT with intravenous administration of etoposide, doxorubicin and cisplatin is currently considered as treatment standard for advanced ACC [8, 9] . Mitotane 500mg tablets are marketed in Europe as Lysodren by HRA Pharma, Paris and in the U.S. by Bristol-Myers Squibb. Treatment with MT is hampered by its severe side effects to the central nervous system (dizziness, speech difficulties, stroke-like symptoms), liver and gastrointestinal tract [10] [11] [12] . While serum concentrations above 14 mg/L have been reported to be associated with the therapeutic response [13] [14] [15] [16] , the incidence of toxic effects increases beyond 20 mg/L leading to a narrow therapeutic window and the requirement of therapeutic drug monitoring. Management is further complicated by unfavourable pharmacokinetic properties of MT. Even at high cumulative doses of 4 to 6 g per day for a consecutive of 3 months, more than half of the patients do not achieve targeted plasma concentration [3, 17] . Overall, MT pharmacokinetics exhibit large inter-individual variability which appears to be due in part due intestinal [18] and/or hepatic metabolism [19] .
The inactive metabolite o,p′-DDA is also found ten times higher in blood than the active parent compound MT [20] [21] [22] . The evidence that MT is strong inducer of hepatic cytochrome-P450 enzyme further strengthens its hepatic metabolism [23] [24] [25] [26] .
MT´s limited aqueous solubility of 0.1 mg/L [27] is likely the cause of poor and variable oral absorption [28] and high volume of distribution [29] . Efforts in the past have been undertaken to shorten the time interval to reach the therapeutic serum/plasma concentrations and reduce the gastrointestinal side effects. Attivi et al. reported a self-micro-emulsifying drug delivery system (SMEDDS). MT was dissolved in various oils and surfactants (in ratio of 1:16) as individual or in the various binary and ternary mixtures (33% caproyl, 33% tween and 33% cremophore EL). The solubility of MT in individual vehicle was maximal with 409 g/L in cremophore EL. The relative bioavailability in rabbits at a dose of 100 mg/kg body weight was increased by a factor of 3.4 for the MT emulsion [30] . Battung and coworkers filed a patent about the development of an oily formulation (SMEDDS) of MT (based on propylene glycol monocaprylate, propylene glycol dicaprate and polyoxyethylene sorbitan monooleate). They were capable to solubilize 0.4 g of MT per gram of oily vehicle (28 wt.%). In vivo studies were conducted in Beagle dogs and the relative bioavailability was increased by factor of 3.2 for the oily formulation [31, 32] .
Lipophilicity of MT has been shown to result in predominant association with serum lipoproteins (LPs) [33, 34] and also chyle [18] but only free MT was demonstrated to be therapeutically active [35, 36] . Collectively, poor aqueous solubility and difficult to predict PK profile of MT are the major obstacles in MT therapy. Here, we aimed at the development of a novel MT nanoformulations, which may enable both an injectable formulation and could increase bioavailability when administered orally and hence shorten the long lag time, which is arguably the biggest problem of MT in the clinics.
Micelles are formed by the self-assembly of amphiphilic molecules. Several polymeric micelles formulations have been widely studied in preclinical and clinical trials which have shown improved pharmacological activity and less systemic toxicity [37] [38] [39] [40] [41] . Poly(2-oxazoline)s (POx) have been discussed as potential biomaterial for decades but the major advancements have been seen in the last few years [42, 43] . In particular, poly(2-methyl-2-oxazoline)-block-poly(2-butyl-2-oxazoline)-block-poly(2-methyl-2-oxazoline) (pMeOx-pBuOx-pMeOx) being the mostly investigated amphiphile has shown a huge potential for not only solubilizing the hydrophobic drugs but also exhibited high cytocompatibility [44, 45] . Accordingly, we set out to develop a novel pMeOx-pBuOx-pMeOx based MT nanoformulation with high drug loading.
The formulation was comprehensively characterized and the bioactivity of the solubilized MT was assessed in 2D and 3D cell culture using NCI-H295 adrenocortical carcinoma cell line.
Our results suggest that this novel MT nanoformulation are suitable for i.v. administration and thus alleviate the biggest clinical problem of MT, its poor bioavailability and unfavourable pharmacokinetics.
Materials and Methods
All substances for the preparation of polymer and bovine serum albumin (BSA) were purchased from Sigma-Aldrich (Steinheim, Germany) or Acros (Geel, Belgium) and were used unless otherwise stated. Mitotane was purchased from ISP chemical products, Columbus, USA. The monomer 2-n-butyl-2-oxazoline (BuOx) was prepared according to the original procedure by Seeliger et al. [46] as modified and reported recently [47] . All substances used for polymerization, methyl trifluoromethylsulfonate (MeOTf), 2-methyl-2-oxazoline and other solvents for polymer preparation were refluxed over CaH 2 , while benzonitrile (PhCN) was refluxed over P 2 O 5 and distilled under argon. Deuterated solvents for NMR analysis were purchased from Deutero GmbH (Kastellaun, Germany). Phosphate-buffered saline (PBS) was prepared by dissolving 8.0 g (137 mmol) NaCl, 0.2 g (2.7 mmol) KCl, 1.42 g (10 mmol) Na 2 HPO 4 and 0.27 g (1.98 mmol) KH 2 PO 4 in 1.0 L of deionized (DI) water (pH 7.4 at 25 °C).
If necessary, pH was adjusted to 7.4 with aqueous HCl or NaOH solution.
Polymer synthesis
The polymerizations and work-up procedures were carried out as described previously [47] [48] [49] . As an example, the synthesis of A-pBuOx-A was performed as follows:
The initiator, MeOTf was added to a dried and argon flushed flask and dissolved in PhCN.
MeOx was added and the reaction mixture was heated to 110 °C for approximately 4 hours.
Reaction progress was controlled by Fourier-transform infrared (FT-IR) and 1 H-NMRspectroscopy. After complete consumption of MeOx, the mixture was cooled to RT and the monomer for the second block (BuOx) was added. The reaction mixture was heated to 120°C
and kept on stirring overnight. The procedure was repeated for the third block (MeOx) and after full monomer consumption was confirmed, termination was carried out by addition of 5 eq. of 1 M NaOH solution in DI water (Polymer batch: P1) or 3 equivalents of piperidine (Polymer batch: P2) at 50°C for 4 hours. Subsequently, 1 eq. of K 2 CO 3 (only in P2) was added and the mixture was stirred at 50°C for 4 hours. PhCN was removed under reduced pressure.
The highly viscous residues were dissolved in DI water and transferred into a dialysis bag (MWCO 1 kDa, cellulose acetate) and dialyzed against DI water for 24 h. The solution was recovered from the bag and lyophilized. The products were obtained as colorless powders.
Methods

Nuclear Magnetic Resonance Spectroscopy (NMR)
NMR spectra were recorded on a Fourier 300 (300.12 MHz), Bruker Biospin (Rheinstetten, Germany) at 298 K. The spectra were calibrated to the signal of residual protonated solvent (CDCl 3 at 7.26 ppm) using MestReNova software.
Dialysis
Dialysis was performed using Spectra/Por membranes with a molecular weight cutoff (MWCO) of 1 kDa (material: cellulose acetate) obtained from neoLab (Heidelberg, Germany). DI water was renewed after 1 h, 4 h and every 12 h subsequently, until end of dialysis.
Gel Permeation Chromatography (GPC)
Gel permeation chromatography (GPC) was performed on an Agilent 1260 Infinity System, Polymer Standard Service (Mainz, Germany) with HFIP containing 3 g/L potassium trifluoroacetate; precolumn: 50 x 8 mm PSS PFG linear M; 2 columns: 300 x 8 mm PSS PFG linear M (particle size 7 μm; pore size 0.1 -1,000 kDa). The columns were kept at 40°C and flow rate was 0.7 mL/min. Prior to each measurement, samples were filtered through 0.2 μm PTFE filters, Roth (Karlsruhe, Germany). Conventional calibration was performed with PEG standards (0.1 -1,000 kg/mol) and data was processed with Win-GPC software.
Drug formulation
Drug loaded polymer micelles were prepared using the thin film method. Ethanolic polymer 
Loading capacity and loading efficiency (LC & LE)
The following equations were used to calculate the loading capacity (LC) and loading efficiency (LE) of the formulations:
where m drug and m excipient are the weight amounts of the solubilized drug and polymer excipient in solution and m drug,added is the weight amount of the drug initially added to the dispersion. No loss of polymer during micelles preparation was assumed.
Long term stability studies
For long term stability studies, formulated MT was stored at ambient conditions (≈ 25 °C) under the exclusion of light. The samples were collected at day 0, 1, 2, 3, 4, 5, 10, 20, and day 30.
Before the determination of the drug loading by HPLC, all samples were centrifuged for 5 min at 10,000 rpm with a 3-Speed micro centrifuge (neoLab, Heidelberg, Germany). Long term stabilization experiments were performed with 3 individually prepared samples and results are presented as means ± SD, quantification was carried out as described above.
Redispersion studies
The freshly prepared formulations were frozen in liquid nitrogen and subjected to 24 h lyophilisation to get the dried powdered MT formulation for redispersion studies. The mediums used for the redispersion (keeping the polymer concentration 10 g/L) were DI water, cell culture medium, PBS and PBS with 40 g/L BSA. The formulations were shaken at 1250 rpm with a Thermomixer comfort (Eppendorf AG, Hamburg, Germany) at room temperature for 10 minutes followed by HPLC analysis as stated in section long term stability studies.
Polymer drug compatibility evaluation by Hansen solubility parameters
The extent of compatibility between MT and the core forming block of the ABA triblock copolymers was calculated by employing the Hildebrand-Scatchard equation [50] :
Where χ drug-polymer (χ dp ) is Flory-Huggins interaction parameter, δdrug and δpolymer are the total solubility parameter (δtotal) for the MT and the core forming block respectively. V is the molar volume of MT calculated by Fedors methods [51] , while R is the gas constant and T is the temperature. The δtotal (also called as three dimensional solubility parameter) i.e δdrug and δpolymer were further calculated by following equations:
The δtotal is the sum of dispersion (δd), polar (δp) and hydrogen bonding forces (δh). The δd, δp and δh were further calculated by Hoftyzer and Van Krevelen's additive group contribution method by employing the following equations:
Where F di , F pi and E hi are the molar dispersion, polar attraction constant and hydrogen bonding energy, respectively. Each structural group in the molecule contribute towards the F di , F pi and
Fourier transform infrared spectroscopy (FT-IR)
The FT-IR spectra were recorded on a FT-IR-4100 (Jasco, Gross-Umstadt, Germany), measuring from 500 cm -1 to 4000 cm -1 . The aqueous MT formulations were lyophilized to obtain the dry powdered formulation prior to FT-IR measurements.
Differential scanning calorimetry (DSC)
DSC was performed on DSC 204 F1 Phoenix equipped with a CC200 F1 Controller, (NETZSCH, Selb, Germany). The dynamic scans were recorded in nitrogen atmosphere with a heating rate of 5°C/min (0°C -200°C). For DSC studies samples were placed into flatbottom aluminum pans with the pierced lids. The aqueous Mt formulations were lyophilized to obtain the dry powdered formulation prior to DSC measurements.
X-Ray diffraction (XRD)
Powder x-ray diffraction (XRD) was performed at STADI P from STOE (STOE & Cie GmbH, Darmstadt Germany). The setup is equipped with radiation source of Cu-Kα and the detector is linear PSD. Measurement were done at 0.15° steps each step lasting 180 s in transmission mode at 40 kV voltage and 30 mA current and 2ϴ angle ranging from 5° to 60° were used.
Dynamic light scattering (DLS)
Dynamic light scattering were measured on Zetasizer Nano ZSP from Malvern, (Malvern Instruments, Worcestershire, UK) in disposable cuvettes (UV cuvettes semi micro, BRAND GmbH, Wertheim, Germany) at ambient temperatures (≈ 25 °C). Data was analysed by using zetasizer software 7.11. All the samples were measured after filtration using 0.45 μm PVDF syringe filter (Rotilabo, Karlsruhe). The filtered sample were further diluted (1:1 ratio with DI water) and measured again to exclude variation due to dilution effect (SI: Figure 8 ). The measurements were recorded as average of three test runs for two individually prepared samples.
Cell culture
The adherent adrenocortical cell line NCI-H295R (ATCC, USA) [52] and HepG2 cell line (ATCC, USA) were grown in DEMEM/F-12 1:1 mix (Gibco, USA) supplemented with 1%
insulin-transferrin-selenium (Gibco, USA) and 3% Nu-Serum (Corning, USA). Cells were cultured at 37°C and 5% CO 2 humid atmosphere in flasks.
Monolayer culture and spheroid formation
For monolayer cell culture, 1x10 5 cells were seeded in a flat bottom 96-well plate in 100 µl and 200 µL medium for cytocompatibility studies and cytotoxicity studies, respectively, and incubated for 24 h. For spheroid formation 5x10 4 cells were seeded in 96-well plates, coated with 50 µL 1.5% autoclaved agarose (Sigma-Aldrich, Germany) in a total volume of 200 µL culture medium. Initially, the spheroid formation was induced by centrifugation at 1 g for 3 min.
Medium was refreshed after 48 h by exchanging 100 µl of supernatant. After 96 h spheroids were formed in each well.
Cytocompatibility studies
The cytocompatibility studies of the polymer alone (both polymer batches, P1 and P2) were performed on monolayer culture of HepG2 cell line and NCI-H295R. The cells were cultured as stated, after 24 h incubation the monolayers were exposed to various polymer concentrations i.e 1, 5, 10, 25, 50 and 100 g/L (prepared in cell culture medium). Treated plates were incubated for 6 h and 24 h. Cell viability was assessed by WST1 (NCI-H295R
and HepG2 cells) and cellTiter-Glo-3D-assay (Promega, Germany) (NCI-H295R). Briefly, after the incubation time of 6 and 24 h the treated plates (with HepG2 cells) were exposed to WST1 reagent (10 µL in each well). The plates were further incubated for 2 h followed by the absorbance measurement by multilabel plate reader Wallac Victor 1420 (PerkinElmer, USA).
CellTiter-Glo-3D assay was performed according to the manufacturer's instructions. 150 µL of supernatant was removed and replaced with 50 µL of CellTiter-Glo-3D-Reagent. Cell lysis was induced by mixing with multichannel pipettes and the lysate was transferred to opaque plates.
After 25 min of incubation luminescence was measured by multilabel plate reader Wallac
Victor 1420 (PerkinElmer, USA).
Cytotoxicity studies in 2D and 3D cell spheroids
The efficacy of MT formulated in micelles or MT dissolved in EtOH was comparatively assed in 2D cell culture and 3D cell spheroids. Mitotane treatment was performed after 24 h of culturing for monolayer and 96 h for spheroids culture in a 96 well-plate, by removing 100 µL medium and adding 100 µL culture medium containing either mitotane-EtOH or mitotane in micelles to attain final concentrations ranging from 5 µM to 75 µM and 50 µM to 200 µM for monolayer and spheroids, respectively. Various stock solutions of mitotane in micelles (2 mM stock solution, prepared in cell culture medium) and mitotane-EtOH (MT was dissolved in absolute ethanol in 500 µM to 20 mM stock solutions) were prepared. Stocks solutions were further diluted with the cell culture medium to obtain final concentrations. EtOH concentration was 1 % (v/v) in all mitotane-EtOH samples and controls. Treated plates were incubated for 24 h and 48 h. All experiments were performed in triplicate with n=8 in each replicate, unless specified otherwise.
Statistical analysis
Statistical analysis was performed using 2-way ANOVA using GraphPad prism software version 5.01. Statistical significance was calculated by applying Bonferroni post hoc tests.
Results and discussions
Polymer synthesis and characterization
Block copolymers of POx are easily accessible by living cationic ring-opening polymerization (LCROP) and POx amphiphiles are highly tunable with respect to to solubility, size, architecture as well chemical functionality [53] [54] [55] [56] . All polymers in this study were also synthesized by LCROP using methyltriflate as an initiator (MeOTf) as previously described [47, 49] . All ABA triblock copolymers comprised hydrophilic pMeOx as block A and poly(2-npropyl-2-oxazoline) (pPrOx), poly(2-n-propyl-2-oxazine) (pPrOzi), poly(2-n-butyl-2-oxazoline) (pBuOx), poly(2-benzyl-2-oxazoline) (pBzOx) and poly(2-n-butyl-2-oxazine) (pBuOzi) as hydrophobic block B, respectively. Two polymer batches of pBuOx based triblock copolymer (P1 and P2) were synthesized specifically for this contribution and terminated with NaOH/water and piperidine, respectively. In our previous work, we have observed relatively minor effect of the polymer termini in poly(2-oxazoline)/poly(2-oxazine) (POx/POzi) based ABA triblock copolymers, but this may have to be assessed on a case-by-case basis [45, 57] .
Both batches were characterized by 1 H-NMR and GPC. A satisfactory synthetic control was achieved in both batches of the polymer, supporting the excellent reproducibility for this polymer synthesis [58] . For further analytical details, please see supporting information
( Figure S1 to S4).
Formulation development
POx based amphiphiles have tremendous potential for formulation development [44, 57, 59 ].
Luxenhofer et al. [57] reported the ultra-high paclitaxel (PTX) loaded POx based micellar formulation with very promising in vivo data. The lead amphiphile is a ABA triblock copolymer, A and B being comprised of hydrophilic poly(2-methyl-2-oxazoline) (pMeOx) and modestly hydrophobic poly(2-butyl-2-oxazoline) (pBuOx), respectively (pMeOx-pBuOx-pMeOx). The loading capacity (LC) was found to be 50 wt.% corresponding to an increase of solubility of This co-formulation demonstrated the superior antitumor efficacy on various small cell and non-small cell lung cancer as compared to single drug micelles or their combination as well as free drug combination [60] .
It is a usual assumption that the hydrophobic block is mainly responsible for solubilisation of hydrophobic drugs and that increasing the hydrophobicity of the core forming block (B) can increase the solubilisation capacity of an amphiphile. More recently, more specific interactions between polymers and their cargo have come into the focus of researchers [61, 62] . In the case of POx based amphiphiles an inverse relationship between the hydrophobicity of the micellar core and the drug loading capacity has been observed repeatedly. Luebtow et al. [48] have Accordingly, the solubilisation of MT, which exhibits an extremely low water solubility [27] zero proton donor groups and higher aromatic character, was tested using five different ABA triblock copolymers including the mostly investigated ABA triblock amphiphile i.e A-pBuOx-A, and A-pPrOzi-A, A-pBuOzi-A, A-pPrOx-A and A-pBzOx-A (Fig 1c) . The polymers with short linear side chain (which has been shown to optimally solubilize various hydrophobic drugs) [47, 57] or with the aromatic content (inspired by a potential benefit of π-π stacking between drug and carrier) [49, 63, 64] were specifically selected to find a good MT solubilizer, for which only very few formulations are reported to date [30, 65] . Using the thin-film approach ( Figure   1b ), we prepared micellar formulations of MT with the aforementioned amphiphilic triblock copolymers. Briefly, the polymer and MT were dissolved in ethanol, which was subsequently removed and the resulting thin-film was dissolved by adding DI water. We kept the targeted polymer concentration at 10 g/L and increased the targeted MT concentration from 2 to 10 g/L. The actual MT concentration achieved in the aqueous phase was assessed using HPLC Table S3 ). ApBuOx-A being the best solubilizer for PTX [57] , also gives the highest MT loading among the tested amphiphiles. Up to 6 g/L (19 mM) MT could be obtained as a clear micellar solution with low viscosity (LC = 36 wt.%). Therefore, the apparent solubility could be increased by a factor of 6x10 4 . Notably, the loading efficiency (LE) did not change much while increasing the MT feed from 2 g/L to 10 g/L, ranging between 55-75 %. As stated previously, from a physiological perspective, one possibility could be that, MT upon oral administration, because of its strong association to lipoproteins enter the lipid transport pathway and MT bound to chylomicrons or their remnants are repeatedly exposed to hepatocytes resulting in higher rate of biotransformation and a much higher inactive metabolite concentration in blood. We postulate the administration of MT injectable formulation will render the optimal MT active metabolite concentration in blood by reducing its hepatic and extra hepatic metabolism. To the best of our knowledge, such high apparent MT aqueous solubility was never reported in the literature. Formulation experiments were performed with both polymer batches (P1 and P2) and no significant difference was observed in loading capacities (supporting info: Table   S2 ). In comparison to A-pBuOx-A, A-pBuOzi also gave good, somewhat lower LC of 27 wt.% (≈ 3.7 g/L). In contrast, A-pPrOzi-A and A-pPrOx-A were much less effective in solubilizing MT with LC of 10 wt.% (≈ 1.3 g/L) and 5 wt.% (≈ 0.5 g/L) respectively. Also, the aromatic A-pBzOx-A was found less efficient than expected [49] but was slightly better than A-pPrOx-A and ApPrOzi-A with LC ≈ 16 wt.% (≈ 2 g/L) (supporting info: Table S1 ). Based on these results, we 
Stability and re-dispersion studies of the formulation
To investigate the potential shelf-life of the formulations (A-pBuOx-A), the freshly prepared MT aqueous solutions were stored at ambient conditions containing the initial precipitate followed by the collection of samples at day 0, 1, 2, 3, 4, 5 and then at day 10, 20, 30. The formulations were centrifuged prior to each measurement. We have previously observed PTX based ApBuOx-A formulations have shown excellent stability up to several months [44, 66] , however, other POx/PTX formulations were much less stable [67] . systematically studied at this point, the lyophilized powders seem to be quite stable at ambient conditions. No deterioration of re-dispersibility was observed over the time course of this study.
Of course, these preliminary studies to not exclude the possibility to extend shelf-life, e.g. by addition of other excipients.
Polymer drug compatibility evaluation by Hansen solubility parameters
The physicochemical compatibility between an active pharmaceutical ingredient and the drug delivery system is believed to be a key factor in the formulation development process to determine the suitability of the drug delivery system. Considering the plethora of drugs with unique physicochemical properties, a universal carrier for all the drugs seems impossible [68] .
There are various ways to assess the drug polymer compatibility [69] [70] [71] [72] which are thought to help to select a suitable carrier for a specific drug in time and cost effective manner. The extent of compatibility between MT and POx based carriers was calculated by the Hansen solubility parameter (HSP) (Table1) [73, 74] . For the further details on HSPs calculations please refer to the supporting info: Table S4 and S5. The extent of compatibility between MT and the core forming blocks was estimated by FloryHuggin's interaction parameters (χ dp ). The lower the value of χ dp the better the polymer/drugs compatibility. Based on the calculated χ dp , MT compatibility with five of selected amphiphiles was in the following order pBuOx≈pPrOzi>pBuOzi>pPrOx>pBzOx. Interestingly, the core forming block pBuOx and pPrOzi are suggested to be best solubilizers for the MT. Being based on group contribution methods, the calculated solubility parameters of pBuOx and pPrOzi, which are structural isomers, yielded identical solubility parameter values and thus, compatibility for the drug MT. Experimentally, however, strong contrast in the solubilisation capacities were found, similar to the situation reported for other drugs [47] . Interestingly, pBzOx was suggested to be the least compatible polymer, even though it features the aromatic system. It is apparent that the experimental results are only partially consistent with the calculated compatibility profile between MT and core forming blocks. It seems that the correct assignment of the best solubilizer, pBuOx is more coincidential and does not indicate that HSP can correctly predict compatibilities in the present system.
Physicochemical characterization of MT nanoformulations
A-pBuOx-A based MT nanoformulations were characterized using FT-IR, DSC, XRD and DLS (with the polymer to drug ratio of 10:2). FT-IR spectroscopy (Figure 3a ) of lyophilized formulation in comparison with the physical mixture, pure drug and pure polymer was performed to characterize potential interactions between MT and polymer. Pure MT is characterized by a number of sharp signals, with particular strong signals in the range of 700 to 800 cm -1 , which are attributed to the -C-Cl stretching vibration. MT also exhibited a characteristic signal at 1490 cm -1 , which is attributed to -C=C-aromatic stretch. While in the physical mixture these signals can still be observed, they completely vanished in the case of nanoformulation. The broader signal at 1630 cm -1 is attributed to the stretching and bending vibration of carbonyl stretch and no noticeable change was observed between the spectra of physical mixture and nanoformulation. Overall, IR suggest very significant interaction between MT and the polymer. As the sharp signals of MT do not shift but significantly broaden to the point of becoming indiscernible these interactions are presumed to be versatile and undefined.
In order to investigate the thermal behaviour of MT nanoformulations, DSC (Figure 3b ) was conducted for pure polymer, pure drug, physical mixture and the lyophilized nanoformulation.
The thermogram of pure drug and its physical mixture with polymer showed an endothermic peak at 80 °C and 78 °C respectively, which represents the characteristic melting peak of MT.
The disappearance of the melting endothermic peak of the drug in the nanoformulation shows that MT is fully amorphous in the lyophilized nanoformulation. Therefore, the lyophilized nanoformulation can be considered a solid amorphous dispersion of MT in A-pBuOx-A.
For further analysis, pure polymer, pristine drug, physical mixture and the lyophilized micellar formulation were analysed by powder-XRD (Figure 3c ). The XRD spectra of the pristine MT shows numerous reflexes in the 2ϴ range of 5 to 40° corresponding to the crystalline nature of MT. The identical spectrum was observed for physical mixture of drug with polymer. In contrast, no signs of crystallinity were observed in case of lyophilized nanoformulation even after 15 days of storage at ambient conditions, confirming the amorphous nature of MT in the nanoformulation. After redispersion, the hydrodynamic radii (R h ) of the micelles was estimated by zeta sizer (Figure 3d and supporting info: Figure S7 ) showing R h ≈40 nm for the pure polymer and R h ≈20 nm for the MT encapsulated micelles. The size distribution by intensity of pure polymer (red) and mitotane formulation (purple) in deionized water after filtration through 0.45 µm PVDF filter.
Cell studies
Cytocompatibility studies on HepG2 and NCI-H295 cell lines
When it comes to the in vivo administration, the safety of the polymer excipients is of great interest. Even though cytocompatibility of POx based amphiphiles has been established several times [45, 57, 75] , cytocompatibility of the presently employed polymer was investigated in HepG2 and NCI-H295 cell lines using WST1 and CellTiter Glo assay (which reflects ATP content) after treatment with polymer solution at different concentrations for 6 h and 24 h. We investigated both polymer batches i.e P1 and P2 by WST1 assay in NCI-H295R
and HepG2 cell lines at concentrations of up to 100 and 50 g/L for P2 and P1, respectively ( Figure 4 a & b; supporting info: Figure S8 ). No sign of cytotoxicity was observed and cell viability remained above 95% in all cases indicating its excellent cytocompatibility. Similar results were obtained using the CellTiter Glo assay (Figure 4c , and supporting info: Figure   S8 ). 
In vitro 2D and 3D cytotoxicity studies of nanoformulations on NCI-H295 cell lines
The cytotoxicity of MT in EtOH and micellar formulation was determined by CellTiter Glo assay in both 2D (monolyer) and 3D (spheroids) NCI-H295R cell lines, for 24 and 48 h. In all the cases dose dependent cytotoxicity was observed.
For the monolayer culture, there was no significant difference in cytotoxicity between MT in EtOH and MT in micelles (p>0.05) upon 24 h incubation (Figure 5a) [76, 77] . Prolonged incubation had no effect on IC50 values (IC 50,48h = 15 and 18 µM for MT in EtOH and micelles, respectively (p>0.05), Figure 5b ). There is growing evidence that cancerous cells grown as spheroids do more accurately mimic the 3D tumor microenvironment when compared to monolayer cultures [78] . Besides activation of cell-cell and cell-matrix interactions, spheroids also simulate some in vivo tumor characteristics such as dormancy, hypoxia, and activation of anti-apoptotic signaling. After 96 h of incubation, we obtained single, uniformly sized and dense spheroids of NCI-H295R cells [77] . In general, when compared to 2D monolayer cells, cancer cells are less sensitive to drugs when analysed in spheroids. This could be attributed to hypoxia and tight cell-cell interactions in spheroids leading to poor permeability, among other factors [79] . Accordingly, we used Interesting to note, in case of spheroids, incubation time did affect cell viability. The IC 50,48h was found to be 47 µM and 43 µM for MT in ethanol and micelles, respectively (Figure 5d 
